Is It Ok for a Breast Cancer Patient to Eat Beef That Is Soybean Fed
JAMA. Author manuscript; available in PMC 2010 Dec 9.
Published in final edited form as:
PMCID: PMC2874068
NIHMSID: NIHMS169338
Soy Food Intake and Breast Cancer Survival
Xiao Ou Shu
1Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center and Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, 2525 West End Avenue, Suite 600, Nashville, TN 37203, USA
Ying Zheng
2Shanghai Institute of Preventive Medicine, 1380 Zhong Shan Road (W), Shanghai, 200336, China
Hui Cai
1Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center and Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, 2525 West End Avenue, Suite 600, Nashville, TN 37203, USA
Kai Gu
1Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center and Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, 2525 West End Avenue, Suite 600, Nashville, TN 37203, USA
Zhi Chen
1Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center and Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, 2525 West End Avenue, Suite 600, Nashville, TN 37203, USA
Wei Zheng
1Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center and Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, 2525 West End Avenue, Suite 600, Nashville, TN 37203, USA
Wei Lu
2Shanghai Institute of Preventive Medicine, 1380 Zhong Shan Road (W), Shanghai, 200336, China
Abstract
Context
Soy foods are rich in isoflavones, a major group of phytoestrogens that have been hypothesized to reduce the risk of breast cancer. However, the estrogen-like effect of isoflavones and the potential interaction between isoflavones and tamoxifen have led to concern about soy food consumption among breast cancer patients.
Objective
To evaluate the association of soy food intake after diagnosis of breast cancer with total mortality and cancer recurrence.
Design, Setting, and Participants
The Shanghai Breast Cancer Survival Study, a large, population-based cohort study of 5,042 female breast cancer survivors. Study participants were recruited between March 2002 and April 2006 and followed through June 2009. Information on cancer diagnosis and treatment, lifestyle exposures after cancer diagnosis, and disease progression was collected at approximately 6 months after cancer diagnosis and was reassessed at three follow-up interviews conducted at 18, 36, and 60 months after diagnosis. Annual record linkage with the Shanghai Vital Statistics Registry database was carried out to obtain survival information for participants who were lost to follow-up. Medical charts were reviewed to verify disease and treatment information.
Main Outcome Measures
Any death and recurrence or breast cancer-related death. Cox regression analysis was carried out with adjustment for known clinical predictors and other lifestyle factors. Soy food intake was treated as a time-dependent variable.
Results
During the median follow-up of 3.9 years (range: 0.5-6.2), 444 deaths and 534 recurrences or breast cancer-related deaths were documented in 5,033 surgically-treated breast cancer patients. Soy food intake, as measured either by soy protein or soy isoflavone intake, was inversely associated with mortality and recurrence. The hazard ratio (HR) associated with highest quartile of soy protein intake was 0.67 (95% confidence interval [CI]=0.51-0.88) for total mortality and 0.66 (95%CI=0.52-0.84) for recurrence compared with the lowest quartile of intake. The multivariate adjusted 5-year mortality rates were 13.1% and 9.2% and 5-year recurrence rates were 13.0% and 8.9%, respectively, for women in the lowest and highest quartiles of soy protein intake. The inverse association was evident among women with either ER‐positive or ER-negative breast cancer and was present in both users and non-users of tamoxifen.
Conclusion
Among women with breast cancer, soy food consumption was significantly associated with decreased risk of death and recurrence.
Introduction
Estrogen is believed to play a central role in breast cancer development and progression. Blocking the effect of estrogen, either by inhibiting estrogen action or by reducing estrogen production, has been widely used in breast cancer treatment as an adjuvant therapy.1 Soy foods are rich in phytoestrogens, mainly in the form of isoflavones, which are natural estrogen receptor modulators that possess both estrogen-like and anti-estrogenic properties. Soy constituents have also been shown to have other anti-cancer effects, including the inhibition of DNA topoisomerase I and II, proteases, tyrosine kinases, inositol phosphate, angiogenesis may also boost immune response, and possess antioxidative effects.2 , 3 Consumption of soy food has been inversely related to the risk of breast cancer in many epidemiological studies.4 - 6 On the other hand, genistein, a major form of isoflavone, has been shown to enhance the proliferation of breast cancer cells in vitro and to promote estrogen-dependent mammary tumor growth in overiectomized rats.3 , 7 In addition, breast cancer treatments often lead to a decrease in the endogenous estrogen supply of survivors, and a concern has been raised as to whether soy isoflavones may exert their estrogenic effects, promote cancer recurrence, and thus negatively influence overall survival.7 , 8 Furthermore, both in vivo and in vitro studies have suggested that soy isoflavones may interact with tamoxifen, although both synergistic and antagonistic interactions have been reported.3 , 10 - 13 To our knowledge, only one epidemiological study, the Life After Cancer Epidemiology (LACE) study, has evaluated the association of post-diagnosis soy isoflavone intake with cancer recurrence. An inverse association was suggested for postmenopausal women who have used tamoxifen.14
Here, we report on a comprehensive evaluation of the association of soy food consumption after diagnosis with breast cancer prognosis using data from a longitudinal study of 5,042 breast cancer patients, with a particular focus on differences in the association according to the ER status of the cancer and tamoxifen use by patients.
Methods
Study population
The current report includes participants of the Shanghai Breast Cancer Survival Study (SBCSS), a longitudinal, population-based study of women who were diagnosed with primary breast cancer 25 and 70 years of age between March 2002 and April 2006 and were permanent residents of Shanghai, China. Patients were identified from the population-based Shanghai Cancer Registry and recruited into the study approximately 6 months after cancer diagnosis. Of the 6,299 cases identified, 5,042 provided written, informed consent and participated in the study (participation rate: 80.0%). For the remaining cases, 757 (12.0%) refused to participate, 258 (4.1%) were absent during study enrollment, 83 (1.3%) could not be contacted, and 159 (2.5%) were excluded for other miscellaneous reasons such as health or communication problems. Non-participants were similar in age at cancer diagnosis, but were more likely to have an advanced stage of cancer than study participants. Nine patients did not receive surgical therapy and were excluded from the analysis, leaving a total of 5,033 subjects for the current study. Cancer diagnoses were confirmed by a combination of medical record review and central review of pathological slides.
Data collection
In-person recruitment and interviews using a structured questionnaire were carried out approximately 6.5 months (standard error: 0.7 months) after cancer diagnosis by trained interviewers who were retired medical professionals. The baseline survey questionnaire covered demographic characteristics, reproductive history, disease history, medication use, selected lifestyle factors, diet, use of complementary and alternative medicine, and quality of life (QOL). Clinical information collected included cancer stage, tumor ER and progesterone receptor (PR) status, and primary treatments (surgery/mastectomy, radiation therapy, chemotherapy, immunotherapy, and/or hormonal therapy such as tamoxifen). Inpatient medical charts were reviewed to verify clinical information. Anthropometric measurements, including height, weight, waist circumference, and hip circumference, were taken according a standard protocol.
Habitual dietary intake was assessed for specific time windows, the preceding 6 months for baseline survey, the preceding 12 months for the 18-month survey, and the preceding 18 months for the 36-month survey. We used a validated food frequency questionnaire15 that was designed to measure consumption of soy foods commonly consumed in Shanghai, including tofu, soy milk and fresh soy beans, and other soy products, as well as meat, fish, and cruciferous vegetables. Nutrient consumption, including soy protein and isoflavone intake, was estimated by summing the product of food intake and the nutrient content of the food item based on the Chinese Food Composition Tables 2002.16
The cohort is being followed by in-person interviews that take place at 18 months, 36 months, and 60 months after cancer diagnosis, supplemented by record linkage to the Shanghai Vital Statistics Registry (Figure 1). The follow-up interviews update soy food intake and complimentary and alternative medicine use and collect information on disease progression and survival status. As of June 30, 2009, the 36-month interview had been completed for 4,344 of 4,936 eligible patients (follow-up rate: 88.2%). The 60-month interview is still ongoing and has been completed for 1,868 patients. Women who completed the 36-month follow-up and women who dropped out had similar intakes of soy food and other foods at the baseline survey. However, the two groups differed in age at diagnosis, BMI, education level, and income, and these factors were adjusted for in the analyses. Outcome information for drop outs was ascertained by annual linkage to the Vital Statistics Registry database. The most recent record linkage was conducted in October 2008. A Charlson comorbidity index was created for each woman based on a validated comorbidity scoring system17 and the diagnostic codes from the International Classification of Disease (ICD-9).18 The institutional review boards of all participating institutions approved the study protocol.
Shanghai Breast Cancer Survival Study Case Recruitment and Follow-up
Statistical analysis
The major endpoints for the study were any death for total mortality and cancer recurrence/metastasis or death related to breast cancer for recurrence analysis. Survival status was censored at the date of last in-person contact or May 31, 2008, 5 months before the most recent linkage to the Vital Statistics Registry, whichever was most recent. For 15 subjects who died of breast cancer but were missing information about disease recurrence, we used the disease stage (tumor node metastasis [TNM])-specific median interval between disease recurrence and death to impute the date of disease recurrence. We excluded 20 patients who had zero disease-free survival time from the recurrence analysis.
Cox proportional hazards models were employed to evaluate the associations of soy intake with mortality and recurrence using age as the time scale.19 Entry time was defined as the age at diagnosis and exit time was defined as the age at event or censoring. Soy protein and soy isoflavone intake were categorized by quartile distribution and were treated as a time-dependent variable in multivariate analysis using a counting process approach to capture the changes in soy intake over the course of the follow-up period.19 We applied the restricted cubic spline function in Cox regression analyses to evaluate the association pattern between soy food intake and morality/recurrence. In these analyses, soy protein/isoflavone intake was treated as a continuous variable; knots were placed at the 5th, 10th, 50th, 90th and 95th percentiles of intake; and the 10th percentile intake was used as the reference.20 Menopausal status at study enrollment was defined as cessation of menstruation for at least 12 months.
Differences in sociodemographic and clinical characteristics across baseline soy food intake categories were evaluated using the Kruskal-Wallis test for continuous variables and χ2 test for categorical variables. We adjusted in the multivariate analyses for known clinical prognosis predictors and lifestyle factors collected at baseline that were related to both soy food intake and survival. These included age at diagnosis, TNM stage, chemotherapy, radiotherapy, type of surgery, BMI, menopausal status, ER and PR status, tamoxifen use, education level, crucifer intake, red meat intake, fish intake, any vitamin supplement use, and physical activity level.
Analyses stratified by the ER status of breast cancer, disease stage, and menopausal status at study enrollment were conducted to evaluate whether these factors modified the associations of soy food intake with overall or disease-free survival. Multiplicative interaction was evaluated using the log likelihood ratio test, which compared the model including only the main effects with the model including both main effects and interactive terms.19
All statistical analyses were performed using SAS software, version 9.1 (SAS Institute, Cary, NC), and all statistical tests were based on two-tailed probability and a significance level set at alpha (α) < 0.05.
Results
After a median follow-up time of 3.9 years (range: 0.5-6.2), 444 deaths and 534 relapses or breast cancer-related deaths were documented in the cohort. As expected, older age at diagnosis, advanced disease stage, negative ER or PR status, high BMI, post-menopausal status, low education level, low income, presence of co-morbidity, having more than 3 pregnancies, and receiving radiotherapy were inversely related to the survival rate, while tamoxifen use and ever use of HRT was positively associated with the survival rate (Table 1).
Table 1
Clinical and Demographic Predictors for Breast Cancer Survival, the Shanghai Breast Cancer Survival Study
| Subject characteristic | N | 5-year overall survival | |||
|---|---|---|---|---|---|
| Deaths | Rate (%) | P | |||
| Age at diagnosis | <40 | 242 | 23 | 89.3 | |
| 40-49 | 2002 | 141 | 91.9 | ||
| 50-59 | 1489 | 134 | 88.6 | ||
| >=60 | 1300 | 146 | 86.4 | <0.01 | |
| Education | None | 190 | 30 | 78.8 | |
| Elementary | 396 | 59 | 82.4 | ||
| Middle or high school | 3642 | 313 | 90.0 | ||
| College and above | 804 | 42 | 93.3 | <0.01 | |
| Income* | <700 | 1403 | 165 | 87.0 | |
| 700-999 | 1484 | 148 | 88.0 | ||
| 1000-1999 | 1541 | 105 | 91.8 | ||
| >=2000 | 602 | 26 | 93.4 | <0.01 | |
| BMI | <25 | 3273 | 267 | 90.3 | |
| 25-29 | 1476 | 138 | 88.7 | ||
| >=30 | 280 | 37 | 83.9 | 0.01 | |
| Menopausal status | Pre | 2461 | 186 | 91.3 | |
| Post | 2572 | 258 | 87.5 | <0.01 | |
| Tamoxifen use | No | 2408 | 250 | 87.5 | |
| Yes | 2622 | 193 | 91.1 | <0.01 | |
| TNM | 0-II | 4318 | 280 | 91.9 | |
| III-IV | 492 | 147 | 65.6 | ||
| Unknown | 223 | 17 | 92.1 | <0.01 | |
| ER status | ER- | 1772 | 224 | 85.2 | |
| ER+ | 3181 | 202 | 92.0 | ||
| Missing | 80 | 18 | 76.5 | <0.01 | |
| PR status | PR- | 2043 | 238 | 86.0 | |
| PR+ | 2894 | 187 | 92.1 | ||
| Missing | 96 | 19 | 79.4 | <0.01 | |
| Chemotherapy | No | 444 | 39 | 88.5 | |
| Yes | 4589 | 405 | 89.5 | 0.95 | |
| Radiotherapy | No | 3418 | 227 | 91.5 | |
| Yes | 1615 | 207 | 84.9 | <0.01 | |
| Radical mastectomy | No | 373 | 29 | 90.6 | |
| Yes | 4660 | 415 | 89.3 | 0.77 | |
| HRT use** | No | 2388 | 250 | 87.0 | |
| Yes | 175 | 8 | 94.6 | 0.01 | |
| Number of pregnancies | 0 | 202 | 21 | 88.7 | |
| 1 | 987 | 91 | 89.1 | ||
| 2 | 1669 | 120 | 91.7 | ||
| 3 | 1168 | 101 | 89.3 | ||
| >3 | 1007 | 111 | 86.5 | 0.03 | |
| Family history of cancer*** | No | 4728 | 423 | 89.3 | |
| Yes | 305 | 21 | 91.1 | 0.29 | |
| Co-morbidity score | 0 | 4031 | 341 | 90.1 | |
| >=1 | 1002 | 103 | 86.7 | 0.06 | |
At the 6-month interview, women who had high levels of soy food intake tended to also have higher intakes of fish and cruciferous vegetables and were more likely to have received chemotherapy, radical mastectomy, drink tea, to have high BMI, to engage in exercise, and to have lower intake of red meat, but were less likely to have received radiotherapy compared with women who had lower levels of soy food consumption (Table 2). Soy food consumption did not vary by education level, income, family history of breast or ovarian cancer, or vitamin supplement use. Alcohol consumption and cigarette smoking are rare in this population and were not related to soy food consumption.
Table 2
Soy Protein Intake at 6 Months Post-Cancer Diagnosis by Demographic Characteristics, Clinical Predictors and Selected Lifestyle Factors, the Shanghai Breast Cancer Survival Study
| Soy Protein Intake (quartiles, g/day) | |||||
|---|---|---|---|---|---|
| | |||||
| Q1(=<5.31)N=1254 | Q2(5.32-9.45)N=1262 | Q3(9.46-15.31)N=1256 | Q4(>15.31)N=1260 | P | |
| Age at diagnosis ( ±SD, year) | 54.2±10.4 | 53.4±10.0 | 53.3±9.9 | 52.9±9.6 | 0.15* |
| Crucifer intake ( ±SD, g/day) | 59.3±42.3 | 67.2±44.6 | 75.6±57.0 | 91.7±59.8 | <0.01* |
| Meat intake ( ±SD, g/day) | 362.6±180.9 | 362.4±183.4 | 353.6±176.4 | 366.8±191.6 | 0.52* |
| Red meat intake ( ±SD, g/day) | 215.0±153.4 | 198.1±156.4 | 186.9±161.2 | 176.2±159.2 | <0.01* |
| White meat intake ( ±SD, g/day) | 88.6±86.6 | 88.7±88.4 | 81.9±79.5 | 91.4±93.3 | 0.32* |
| Fish intake ( ±SD, g/day) | 48.8±59.9 | 62.0±69.1 | 68.8±72.0 | 78.8±77.0 | <0.01* |
| BMI ( ±SD) | 23.8±3.5 | 24.0±3.3 | 24.0±3.3 | 24.5±3.5 | <0.01* |
| Number of pregnancies ( ±SD) | 1.5±1.4 | 2.5±1.4 | 2.5±1.4 | 2.4±1.4 | 0.47* |
| Education level (%) | |||||
| None | 5.0 | 3.1 | 3.7 | 3.3 | |
| Primary school | 9.1 | 7.5 | 7.5 | 7.4 | |
| Middle or high school | 70.2 | 73.4 | 72.4 | 73.4 | |
| College and above | 15.6 | 16.0 | 16.4 | 15.9 | 0.21 |
| Income (%)** | |||||
| <700 | 28.1 | 27.7 | 27.6 | 28.1 | |
| 700-999 | 30.7 | 30.4 | 30.2 | 26.8 | |
| 1000-1999 | 30.3 | 28.9 | 30.4 | 33.0 | |
| >2000 | 10.9 | 13.1 | 11.8 | 12.1 | 0.32 |
| Post-menopausal (%) | 52.6 | 51.4 | 49.4 | 50.9 | 0.45 |
| Tamoxifen user (%) | 53.0 | 52.7 | 53.3 | 49.5 | 0.20 |
| ER status (%) | |||||
| Negative | 33.8 | 35.3 | 35.4 | 36.3 | |
| Positive | 64.4 | 63.2 | 63.2 | 62.0 | |
| Missing | 1.8 | 1.5 | 1.4 | 1.7 | 0.85 |
| PR status (%) | |||||
| Negative | 40.1 | 40.9 | 39.3 | 42.1 | |
| Positive | 57.9 | 57.4 | 59.0 | 55.6 | |
| Missing | 2.0 | 1.7 | 1.7 | 2.3 | 0.63 |
| TNM stage (%) | |||||
| 0-I | 37.2 | 37.5 | 35.4 | 35.7 | |
| IIA | 32.1 | 32.1 | 33.9 | 32.6 | |
| IIB+ | 15.2 | 16.4 | 18.5 | 16.4 | |
| III-IV | 11.1 | 9.7 | 8.2 | 10.1 | |
| Missing | 4.3 | 4.3 | 4.00 | 5.2 | 0.32 |
| Received chemotherapy (%) | 89.2 | 91.1 | 91.9 | 92.5 | 0.03 |
| Received radiotherapy (%) | 32.9 | 32.9 | 33.6 | 29.1 | 0.06 |
| Received radical mastectomy (%) | 90.7 | 92.2 | 93.6 | 93.8 | 0.01 |
| Family history of cancer (%)*** | 5.4 | 5.6 | 6.6 | 6.6 | 0.46 |
| HRT user (%) **** | 6.1 | 6.3 | 7.1 | 7.8 | 0.60 |
| Regular smoker (%) | 2.1 | 2.5 | 3.0 | 2.9 | 0.43 |
| Regular alcohol drinker (%) | 2.5 | 2.9 | 3.6 | 3.3 | 0.42 |
| Regular tea drinker (%) | 20.4 | 22.0 | 26.2 | 26.8 | <0.01 |
| Ginseng user (%) | 13.6 | 13.9 | 13.9 | 15.9 | 0.30 |
| Vitamin supplement use (%) | 25.6 | 28.8 | 28.7 | 34.3 | <0.01 |
| Regular physical activity (%) | 57.1 | 62.0 | 67.0 | 72.2 | <0.01 |
| Comorbidity score >=1 (%) | 21.2 | 19.6 | 18.6 | 20.2 | 0.42 |
Soy food consumption after cancer diagnosis, measured as soy protein intake, was inversely associated with mortality and recurrence (Table 3). The hazard ratios comparing the highest to lowest quartiles of soy protein intake were 0.67 (95%CI= 0.51-0.88) for total mortality and 0.66 (95%CI= 0.52-0.84) for recurrence. The corresponding HRs were 0.76 (95%CI= 0.58-0.99) for mortality and 0.74 (95%CI= 0.59-0.95) for recurrence, when soy isoflavone intake was considered. The associations of soy protein/isoflavone intake with mortality and recurrence appear to follow a linear, dose- response pattern until soy protein intake reaches 11 gram/day (or soy isoflavone intake, 40 mg/day). After these points, the association appeared to level off or even re-bound (Figures 2 and 3). The multivariate adjusted mortality and recurrence rate by soy protein intake are shown in Figures 4 and 5.
Association Pattern for Soy Protein Intake and Breast Cancer Outcomes
Association Pattern for Soy Isoflavone Intake an Breast Cancer Outcomes
Total Mortality by Soy Protein Intake
Breast Cancer Recurrence by Soy Protein Intake
Table 3
Soy Food Intake in Association With Overall and Disease-Free Survival, the Shanghai Breast Cancer Survival Study
| Total Mortality | Relapse/Breast Cancer-Specific Mortality | |||||
|---|---|---|---|---|---|---|
| | ||||||
| No. of Participants | No. of Events | HR (95%CI) | No of Events | HR (95%CI) | ||
| Soy protein intake | ||||||
| =<5.31 | 1254 | 117 | 1.0 | 137 | 1.0 | |
| 5.32-9.45 | 1262 | 95 | 0.74(0.57-0.97) | 136 | 0.76(0.60-0.96) | |
| 9.46-15.31 | 1256 | 112 | 0.68(0.52-0.89) | 128 | 0.67(0.52-0.86) | |
| >15.31 | 1260 | 120 | 0.67(0.51-0.88) | 133 | 0.66(0.52-0.84) | |
| Isoflavone intake | ||||||
| =<20.00 | 1256 | 119 | 1.0 | 144 | 1.0 | |
| 20.01-36.50 | 1259 | 83 | 0.71(0.55-0.93) | 116 | 0.83(0.66-1.05) | |
| 36.51-62.68 | 1258 | 123 | 0.73(0.56-0.96) | 141 | 0.64(0.50-0.82) | |
| >62.68 | 1259 | 119 | 0.76(0.58-0.99) | 133 | 0.74(0.59-0.95) | |
| Women with ER-Negative Breast Cancer | ||||||
| Soy protein intake | =<5.31 | 424 | 54 | 1.0 | 65 | 1.0 |
| 5.32-9.45 | 446 | 46 | 0.81(0.56-1.16) | 64 | 0.93(0.67-1.29) | |
| 9.46-15.31 | 445 | 60 | 0.60(0.40-0.89) | 66 | 0.66(0.46-0.96) | |
| >15.31 | 457 | 64 | 0.75(0.52-1.10) | 72 | 0.76(0.53-1.08) | |
| Isoflavone intake | =<20.00 | 424 | 54 | 1.0 | 67 | 1.0 |
| 20.01-36.50 | 441 | 38 | 0.80(0.55-1.17) | 55 | 1.01(0.72-1.40) | |
| 36.51-62.68 | 447 | 67 | 0.74(0.50-1.08) | 72 | 0.61(0.42-0.88) | |
| >62.68 | 460 | 65 | 0.83(0.57-1.21) | 73 | 0.87(0.61-1.23) | |
| Women with ER-Positive Breast Cancer | ||||||
| Soy protein intake | =<5.31 | 808 | 55 | 1.0 | 67 | 1.0 |
| 5.32-9.45 | 797 | 47 | 0.75(0.50-1.12) | 69 | 0.69(0.48-0.98) | |
| 9.46-15.31 | 794 | 49 | 0.83(0.56-1.21) | 60 | 0.75(0.54-1.06) | |
| >15.31 | 781 | 51 | 0.62(0.41-0.93) | 59 | 0.65(0.46-0.92) | |
| Isoflavone intake | =<20.00 | 813 | 57 | 1.0 | 72 | 1.0 |
| 20.01-36.50 | 796 | 43 | 0.71(0.48-1.07) | 58 | 0.78(0.55-1.11) | |
| 36.51-62.68 | 796 | 52 | 0.79(0.54-1.17) | 67 | 0.75(0.53-1.07) | |
| >62.68 | 775 | 50 | 0.73(0.49-1.08) | 58 | 0.73(0.52-1.03) | |
| P for interaction | Soy protein | 0.35 | 0.34 | |||
| P for interaction | Isoflavones | 0.88 | 0.28 | |||
The associations of soy food intake with mortality and recurrence were observed for women with either ER-positive breast cancer or ER-negative breast cancer (Table 3). The association between soy food intake and total mortality did not appear to vary by menopausal status (Table 4) or by cancer stage (Table 5). Excluding 156 women with stage 0 breast cancer did not change the results.
Table 4
Soy Food in Association with Overall and Disease-Free Survival by Menopausal Status at Cancer Diagnosis, the Shanghai Breast Cancer Survival Study
| No. of participants | Total mortality | Relapse/Breast Cancer Specific Deaths | |||||
|---|---|---|---|---|---|---|---|
| | |||||||
| No. of Events | HR | No. of Events | HR | ||||
| Pre-menopausal women | |||||||
| Soy protein intake | =<5.31 | 594 | 43 | 1.0 | 58 | 1.0 | |
| 5.32-9.45 | 613 | 42 | 0.82(0.55-1.22) | 62 | 0.78(0.55-1.11) | ||
| 9.46-15.31 | 635 | 48 | 0.58(0.38-0.89) | 62 | 0.61(0.42-0.88) | ||
| >15.31 | 618 | 53 | 0.66(0.44-0.98) | 60 | 0.66(0.46-0.94) | ||
| Isoflavone intake | =<20.00 | 585 | 44 | 1.0 | 58 | 1.0 | |
| 20.01-36.50 | 612 | 35 | 0.80(0.54-1.20) | 53 | 0.82(0.58-1.16) | ||
| 36.51-62.68 | 631 | 51 | 0.55(0.36-0.85) | 66 | 0.51(0.34-0.74) | ||
| >62.68 | 632 | 56 | 0.74(0.50-1.11) | 65 | 0.74(0.52-1.05) | ||
| Post-menopausal women | |||||||
| Soy protein intake | =<5.31 | 660 | 74 | 1.0 | 79 | 1.0 | |
| 5.32-9.45 | 649 | 53 | 0.70(0.49-0.99) | 74 | 0.76(0.55-1.05) | ||
| 9.46-15.31 | 621 | 64 | 0.80(0.57-1.14) | 66 | 0.73(0.53-1.02) | ||
| >15.31 | 642 | 67 | 0.68(0.48-0.97) | 73 | 0.66(0.48-0.93) | ||
| Isoflavone intake | =<20.00 | 671 | 75 | 1.0 | 86 | 1.0 | |
| 20.01-36.50 | 647 | 48 | 0.67(0.47-0.97) | 63 | 0.87(0.63-1.20) | ||
| 36.51-62.68 | 627 | 72 | 0.92(0.66-1.29) | 75 | 0.78(0.56-1.09) | ||
| >62.68 | 627 | 63 | 0.77(0.54-1.10) | 68 | 0.75(0.54-1.05) | ||
| P for interaction | Soy protein | 0.40 | 0.74 | ||||
| P for interaction | Isoflavones | 0.07 | 0.22 | ||||
Table 5
Soy Food Intake in Association with Overall and Disease-Free Survival by TNM stage, the Shanghai Breast Cancer Survival Study
| Total Mortality | Relapse/Breast Cancer-Specific Mortality | ||
|---|---|---|---|
| | |||
| HR (95%CI) | HR (95%CI) | ||
| Stage I, II, III and IV | |||
| Soy protein intake | =<5.31 | 1.0 | 1.0 |
| 5.32-9.45 | 0.77(0.59-1.01) | 0.77(0.61-0.98) | |
| 9.46-15.31 | 0.65(0.49-0.86) | 0.64(0.5-0.83) | |
| >15.31 | 0.70(0.53-0.92) | 0.70(0.54-0.89) | |
| P for interaction | 0.15 | ||
| Isoflavone intake | =<20.00 | 1.0 | 1.0 |
| 20.01-36.50 | 0.74(0.57-0.97) | 0.78(0.60-1.03) | |
| 36.51-62.68 | 0.70(0.54-0.92) | 0.63(0.49-0.82) | |
| >62.68 | 0.78(0.60-1.03) | 0.77(0.60-0.98) | |
| P for interaction | 0.83 | ||
| Stage I | |||
| Soy protein intake | =<5.31 | 1.0 | 1.0 |
| 5.32-9.45 | 0.62(0.29-1.32) | 0.68(0.34-1.35) | |
| 9.46-15.31 | 0.74(0.36-1.54) | 0.84(0.44-1.62) | |
| >15.31 | 0.72(0.34-1.53) | 0.79(0.40-1.55) | |
| Isoflavone intake | =<20.00 | 1.0 | 1.0 |
| 20.01-36.50 | 0.92(0.43-1.96) | 0.78(0.40-1.54) | |
| 36.51-62.68 | 0.94(0.45-1.99) | 0.86(0.45-1.66) | |
| >62.68 | 0.90(0.41-1.96) | 0.85(0.43-1.67) | |
| Stage II | |||
| Soy protein intake | =<5.31 | 1.0 | 1.0 |
| 5.32-9.45 | 1.17(0.8-1.72) | 0.95(0.68-1.31) | |
| 9.46-15.31 | 0.92(0.62-1.37) | 0.71(0.50-1.00) | |
| >15.31 | 0.93(0.62-1.39) | 0.70(0.49-1.00) | |
| Isoflavone intake | =<20.00 | 1.0 | 1.0 |
| 20.01-36.50 | 0.85(0.57-1.25) | 0.87(0.62-1.21) | |
| 36.51-62.68 | 0.91(0.62-1.33) | 0.67(0.48-0.95) | |
| >62.68 | 0.98(0.67-1.44) | 0.74(0.53-1.05) | |
| Stage III and IV | |||
| Soy protein intake | =<5.31 | 1.0 | 1.0 |
| 5.32-9.45 | 0.51(0.32-0.82) | 0.57(0.37-0.89) | |
| 9.46-15.31 | 0.45(0.27-0.73) | 0.56(0.35-0.88) | |
| >15.31 | 0.47(0.30-0.74) | 0.60(0.39-0.92) | |
| Isoflavone intake | =<20.00 | 1.0 | 1.0 |
| 20.01-36.50 | 0.63(0.40-0.99) | 0.79(0.52-1.20) | |
| 36.51-62.68 | 0.45(0.27-0.75) | 0.53(0.33-0.86) | |
| >62.68 | 0.53(0.34-0.85) | 0.73(0.47-1.12) | |
Tamoxifen was associated with reduced risk of relapse or breast cancer-specific mortality among women with ER-positive breast cancer (HR=0.77, 95%CI=0.59-1.02, data not shown in tables). Given that soy isoflavones and tamoxifen both bind to ER, we evaluated the combined effect of soy food intake and tamoxifen use on survival among women with ER-positive breast cancer (Table 6). We found that women in the highest soy food intake groups had the lowest mortality and recurrence rate compared with women in the lowest soy food intake group, regardless of tamoxifen use status. The inverse association of tamoxifen use and recurrence, on the other hand, was only seen among women with low to moderate levels of soy food intake. Among women whose soy food intake was in the highest quartiles, tamoxifen use did not appear to confer any additional benefit. The HRs for recurrence associated with the highest quartile of soy protein intake were 0.61 (95%CI=0.34-1.10) for non-users of tamoxifen and 0.60 (95%CI=0.36-1.00 for tamoxifen users, both of which were lower than the HRs among women who were in the lowest quartile of soy food intake and used tamoxifen (HR=0.91, 95%CI=0.56-1.47). These point estimates were not statistically significant due to the small sample size. Tests for multiplicative interaction between soy intake and tamoxifen use were not statistically significant.
Table 6
Soy Food Intake and Tamoxifen Use in Association with Overall and Disease-Free Survival Among Women with ER-Positive Breast Cancer, the Shanghai Breast Cancer Survival Study
| Total mortality | Relapse and Breast Cancer Specific mortality | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| | |||||||||||
| Tamoxifen use | Tamoxifen use | ||||||||||
| No | Yes | No | Yes | ||||||||
| No. of participants | No. of events | HR (95%CI) | No. of participants | No. of events | HR (95%CI) | No. of events | HR (95%CI) | No. of events | HR (95%CI) | ||
| Soy protein intake | =<5.31 | 249 | 20 | 1.0 | 559 | 35 | 0.87(0.50-1.52) | 25 | 1.0 | 42 | 0.91(0.56-1.47) |
| 5.32-9.45 | 248 | 14 | 0.61(0.31-1.22) | 548 | 32 | 0.72(0.41-1.27) | 24 | 0.71(0.40-1.28) | 44 | 0.61(0.36-1.03) | |
| 9.46-15.31 | 240 | 24 | 1.14(0.63-2.05) | 554 | 25 | 0.56(0.31-1.02) | 25 | 1.04(0.61-1.77) | 35 | 0.55(0.32-0.92) | |
| >15.31 | 275 | 18 | 0.60(0.30-1.18) | 506 | 33 | 0.54(0.30-0.97) | 22 | 0.61(0.34-1.10) | 37 | 0.60(0.36-1.00) | |
| P for interaction | 0.19 | 0.30 | |||||||||
| Isoflavone intake | =<20.00 | 253 | 20 | 1.0 | 560 | 37 | 0.88(0.51-1.54) | 25 | 1.0 | 47 | 0.88(0.54-1.44) |
| 20.01-36.50 | 253 | 13 | 0.71(0.36-1.39) | 542 | 29 | 0.63(0.35-1.13) | 22 | 0.83(0.46-1.48) | 35 | 0.67(0.40-1.12) | |
| 36.51-62.68 | 237 | 26 | 1.04(0.57-1.90) | 559 | 26 | 0.57(0.31-1.04) | 28 | 0.97(0.57-1.66) | 39 | 0.55(0.32-0.94) | |
| >62.68 | 269 | 17 | 0.69(0.35-1.34) | 506 | 33 | 0.66(0.38-1.17) | 21 | 0.68(0.38-1.22) | 37 | 0.67(0.41-1.10) | |
| P for interaction | 0.50 | 0.48 | |||||||||
Discussion
Although soy food consumption among US women is substantially lower than among women in China (the average isoflavone intake among US women is 1-6 mg/day21 compared with 47 grams/day in our study population), soy food consumption in the United States has been increasing rapidly. The proportion of people eating soy products at least once per week was 28% in 2003, up from 15% in 1997.22 Although soy constituents have been shown to possess anti-cancer properties1 - 7 and improve cardiovascular and bone health,23 - 25 the estrogen-like effect of soy isoflavones1 , 3 , 7 , 8 and conflicting data from in vivo and in vitro studies regarding the role of soy constituents in stimulating cell proliferation3 , 7 have raised a concern about the safety of soy food consumption among breast cancer survivors.7 , 8 , 26 Because concentrated soy isoflavones are increasingly being added to a wide variety of foods, including beverages, nutrition bars, yogurt, baked goods, meal replacements, and confections, exposure to isoflavones is becoming ubiquitous, which is heightening concern about soy food consumption among the rapidly growing population of breast cancer survivors. In our comprehensive evaluation of soy food consumption and breast cancer outcomes using data from a large, population-based cohort study, we found that soy food intake was inversely associated with mortality and recurrence. The inverse association did not appear to vary by menopausal status and was evident for women with both ER-positive and ER-negative cancer and early and late stage cancer.
Among the many constituents of soy food, soy isoflavones are the most intensively studied phytochemicals for their health-related effects. It has been shown that soy isoflavones compete with endogenous estrogens in the binding of estrogen receptors, increase the synthesis of sex-hormone-binding globulin (thus lowering the biological availability of sex hormones), inhibit 17β-hydroxysteroid dehydrogenases (thus reducing estrogen synthesis), and increase clearance of steroids from the circulation.2 , 3 These anti-estrogenic effects may be one of the underlying mechanisms through which soy food consumption is associated with better breast cancer outcomes.
We did not find that risk estimates associated with soy isoflavone intake were stronger than risk estimates associated with soy protein intake. This may be due to the fact that measurement errors related to the assessment of isoflavone intake are larger than measurements errors related to soy protein intake. On the other hand, these results may also suggest that other known and unknown constituents of soy foods, such as folate, protein, protease inhibitor, calcium, or fiber, individually or in combination are responsible for the survival benefits of soy food consumption. It has been previously reported in some studies that the health effects of soy supplements and soy isoflavone supplements may differ. For example, soy milk supplements have been found to reduce circulating levels of estrogen,27 - 29 while soy isoflavone supplements failed to do so.30 Similarly, soy milk or soy protein supplements were found to relieve menopausal symptoms,31 - 33 while soy isoflavone supplements showed no effect.34 More studies are needed to replicate our findings and to disentangle whether the benefit of soy food consumption on breast cancer prognosis is the result of soy isoflavones or other soy constituents or is the result of a combination of the effects of multiple soy constituents.
In our study population, soy food intake was associated with other characteristics of a healthy lifestyle, including more exercise, high vegetable and fish intake, and low red meat intake. Earlier studies have shown that high vegetable intake may be related to an improved survival rate, although evidence is not entirely consistent.35 - 37 We carefully adjusted for other dietary intake and lifestyle factors in our analyses. However, residual confounding resulting from measurement errors or unmeasured lifestyle factors could not be entirely ruled out, which would likely lead to an underestimation of the true association. Another concern is that reverse causation, i.e., poor health and appetite among breast cancer patients who had subclinical relapse, could lead to a reduction of soy food consumption. If this were true, we would expect to see that other dietary intakes were also inversely related to survival. However, in our study, meat consumption was not associated with breast cancer survival, which argues against reverse causation.
Because isoflavones and tamoxifen both bind to estrogen receptors and because of the conflicting results from in vivo and in vitro studies, which have reported both synergetic and antagonistic effects between isoflavones and tamoxifen use, there is a concern that soy isoflavones may affect the efficacy of this widely-used adjuvant treatment for breast cancer. In our study, we found that soy food intake was associated with improved survival regardless of tamoxifen use, while tamoxifen use was only related to improved survival among women who had low or moderate levels of soy isoflavone intake. Tamoxifen was not related to further improvement of survival rates among women who had the highest level of soy isoflavone intake. More importantly, women who had the highest level of soy food intake and who did not take tamoxifen had a lower risk of mortality and a lower recurrence rate than women who had the lowest level of soy food intake and used tamoxifen, suggesting that high soy food intake and tamoxifen use may have a comparable effect on breast cancer outcomes.
Our study is the largest population-based study of breast cancer survival to date and was specifically designed to evaluate the influence of soy food intake on breast cancer outcomes. Soy food intake was assessed using a validated dietary questionnaire and was updated during the course of follow-up. The high response rate and ability to adjust for other lifestyle factors also improved the quality of our study.
However, the follow-up period of our study is still relatively short, which prevented an evaluation of the long-term effects of soy intake on breast cancer outcomes. Continued follow-up of the cohort would overcome this limitation. Our study also has limited statistical power for sub-analyses (e.g. ER status, tamoxifen use status).
In summary, in this population-based prospective study, we found that soy food intake is safe and was associated with lower mortality and recurrence among breast cancer patients. The association of soy food intake with mortality and recurrence appears to follow a linear, dose-response pattern until soy food intake reached 11 grams of soy protein per day; no additional benefits on mortality and recurrence were observed with higher intakes of soy food. This study suggests that moderate soy food intake is safe and potentially beneficial for women with breast cancer.
Acknowledgments
Funding/Support: This study was supported by grants from the Department of Defense Breast Cancer Research Program (DAMD 17-02-1-0607) and the National Cancer Institute (R01 CA118229). The funding organizations had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; or preparation and approval of the manuscript. The content of the information does not necessarily reflect the position or the policy of the Government, and no official endorsement should be inferred.
Additional Contributions: We thank Dr. Fan Jin, M.D., a paid consultant for the Shanghai Institute of Preventive Medicine, for her support of the study's implementation. She received compensation for her assistance. We thank Ms. Bethanie Hull, B.A., Vanderbilt University, for her assistance in manuscript preparation. She received salary support from the grants. We thank the participants and staff members of the Shanghai Breast Cancer Survival Study for making this study possible.
Footnotes
Author Contributions: XOS and WZ conceived and designed the study; YZ, KG, and WL acquired the data; XOS, HC, and ZC analyzed and interpreted the data; XOS drafted the manuscript; XOS, YZ, HC, KG, ZC, WZ, and WL provided critical review of the manuscript for important intellectual content; HC provided the statistical analysis; XOS and WZ obtained the funding; YZ, KG, CZ, and WL provided administrative, technical, or material support; and XOS and WL provided supervision.
XOS had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.
Conflicts of Interest: XOS received a small research development fund from the United Soybean Board in 2005. The United Soybean Board played no role in the design, implementation, or result interpretation of this study or in the preparation or approval of the manuscript. No other authors have any conflicts of interest to declare.
References
1. Mouridsen HT, Rose C, Brodie AH, Smith IE. Challenges in the endocrine management of breast cancer. Breast. 2003;12 2:S2–19. [PubMed] [Google Scholar]
2. Adlercreutz H, Mazur W. Phyto-oestrogens and Western diseases. Ann Med. 1997;29(2):95–120. [PubMed] [Google Scholar]
3. Taylor CK, Levy RM, Elliott JC, Burnett BP. The effect of genistein aglycone on cancer and cancer risk: a review of in vitro, preclinical, and clinical studies. Nutr Rev. 2009;67(7):398–415. [PubMed] [Google Scholar]
4. Trock BJ, Hilakivi-Clarke L, Clarke R. Meta-analysis of soy intake and breast cancer risk. J Natl Cancer Inst. 2006;98(7):459–471. [PubMed] [Google Scholar]
5. Wu AH, Yu MC, Tseng CC, Pike MC. Epidemiology of soy exposures and breast cancer risk. Br J Cancer. 2008;98(1):9–14. [PMC free article] [PubMed] [Google Scholar]
6. Lee SA, Shu XO, Li H, et al. Adolescent and adult soy food intake and breast cancer risk: results from the Shanghai Women's Health Study. Am J Clin Nutr. 2009;89(6):1920–1926. [PMC free article] [PubMed] [Google Scholar]
7. Helferich WG, Andrade JE, Hoagland MS. Phytoestrogens and breast cancer: a complex story. Inflammopharmacology. 2008;16(5):219–226. [PubMed] [Google Scholar]
8. Velentzis LS, Woodside JV, Cantwell MM, Leathem AJ, Keshtgar MR. Do phytoestrogens reduce the risk of breast cancer and breast cancer recurrence? What clinicians need to know. Eur J Cancer. 2008;44(13):1799–1806. [PubMed] [Google Scholar]
9. Constantinou AI, White BE, Tonetti D, et al. The soy isoflavone daidzein improves the capacity of tamoxifen to prevent mammary tumours. Eur J Cancer. 2005;41(4):647–654. [PubMed] [Google Scholar]
10. Tanos V, Brzezinski A, Drize O, Strauss N, Peretz T. Synergistic inhibitory effects of genistein and tamoxifen on human dysplastic and malignant epithelial breast cells in vitro. Eur J Obstet Gynecol Reprod Biol. 2002;102(2):188–194. [PubMed] [Google Scholar]
11. Shen F, Xue X, Weber G. Tamoxifen and genistein synergistically down-regulate signal transduction and proliferation in estrogen receptor-negative human breast carcinoma MDA-MB-435 cells. Anticancer Res. 1999;19(3A):1657–1662. [PubMed] [Google Scholar]
12. Ju YH, Doerge DR, Allred KF, Allred CD, Helferich WG. Dietary genistein negates the inhibitory effect of tamoxifen on growth of estrogen-dependent human breast cancer (MCF-7) cells implanted in athymic mice. Cancer Res. 2002;62(9):2474–2477. [PubMed] [Google Scholar]
13. Schwartz JA, Liu G, Brooks SC. Genistein-mediated attenuation of tamoxifen-induced antagonism from estrogen receptor-regulated genes. Biochem Biophys Res Commun. 1998;253(1):38–43. [PubMed] [Google Scholar]
14. Guha N, Kwan ML, Quesenberry CP, Jr, et al. Soy isoflavones and risk of cancer recurrence in a cohort of breast cancer survivors: the Life After Cancer Epidemiology study. Breast Cancer Res Treat. 2009 [PMC free article] [PubMed] [Google Scholar]
15. Shu XO, Yang G, Jin F, et al. Validity and reproducibility of the food frequency questionnaire used in the Shanghai Women's Health Study. Eur J Clin Nutr. 2004;58(1):17–23. [PubMed] [Google Scholar]
16. Yang YX, Wang GY, Pan XC. Chinese Food Composition Tables 2002. Beijing: Beijing University Medical Press; 2002. [Google Scholar]
17. Grunau GL, Sheps S, Goldner EM, Ratner PA. Specific comorbidity risk adjustment was a better predictor of 5-year acute myocardial infarction mortality than general methods. J Clin Epidemiol. 2006;59(3):274–280. [PubMed] [Google Scholar]
18. The International Classification of Diseases. Department of Health and Human Services. 9th Rev. Washington, DC: US Government Printing Office; 1998. ICD-9-CM. [Google Scholar]
19. Hosmer DW, Jr, Lemeshow S. Applied survival analysis: regression modeling of time to event data. New York: John Wiley and Sons, Inc.; 1999. [Google Scholar]
20. Harrell FG., Jr . Regression Modeling Strategies: with Applications to Linear Models, Logistic Regression, and Survival Analysis. New York City: Springer-Verlag; 2001. [Google Scholar]
21. Horn-Ross PL, John EM, Canchola AJ, Stewart SL, Lee MM. Phytoestrogen intake and endometrial cancer risk. J Natl Cancer Inst. 2003;95(15):1158–1164. [PubMed] [Google Scholar]
23. Cassidy A, Hooper L. Phytoestrogens and cardiovascular disease. J Br Menopause Soc. 2006;12(2):49–56. [PubMed] [Google Scholar]
24. Clarkson TB. Soy, soy phytoestrogens and cardiovascular disease. J Nutr. 2002;132(3):566S–569S. [PubMed] [Google Scholar]
25. Ishimi Y. Soybean isoflavones in bone health. Forum Nutr. 2009;61:104–116. [PubMed] [Google Scholar]
26. Messina MJ, Wood CE. Soy isoflavones, estrogen therapy, and breast cancer risk: analysis and commentary. Nutr J. 2008;7:17. [PMC free article] [PubMed] [Google Scholar]
27. Nagata C, Takatsuka N, Inaba S, Kawakami N, Shimizu H. Effect of soymilk consumption on serum estrogen concentrations in premenopausal Japanese women. J Natl Cancer Inst. 1998;90(23):1830–1835. [PubMed] [Google Scholar]
28. Lu LJ, Anderson KE, Grady JJ, Nagamani M. Effects of soya consumption for one month on steroid hormones in premenopausal women: implications for breast cancer risk reduction. Cancer Epidemiol Biomarkers Prev. 1996;5(1):63–70. [PubMed] [Google Scholar]
29. Cassidy A, Bingham S, Setchell KD. Biological effects of a diet of soy protein rich in isoflavones on the menstrual cycle of premenopausal women. Am J Clin Nutr. 1994;60(3):333–340. [PubMed] [Google Scholar]
30. Duncan AM, Merz BE, Xu X, et al. Soy isoflavones exert modest hormonal effects in premenopausal women. J Clin Endocrinol Metab. 1999;84(1):192–197. [PubMed] [Google Scholar]
31. Albertazzi P, Pansini F, Bonaccorsi G, et al. The effect of dietary soy supplementation on hot flushes. Obstet Gynecol. 1998;91(1):6–11. [PubMed] [Google Scholar]
32. Murkies AL, Lombard C, Strauss BJ, et al. Dietary flour supplementation decreases post-menopausal hot flushes: effect of soy and wheat. Maturitas. 1995;21(3):189–195. [PubMed] [Google Scholar]
33. Washburn S, Burke GL, Morgan T, Anthony M. Effect of soy protein supplementation on serum lipoproteins, blood pressure, and menopausal symptoms in perimenopausal women. Menopause. 1999;6(1):7–13. [PubMed] [Google Scholar]
34. Quella SK, Loprinzi CL, Barton DL, et al. Evaluation of soy phytoestrogens for the treatment of hot flashes in breast cancer survivors: A North Central Cancer Treatment Group Trial. J Clin Oncol. 2000;18(5):1068–1074. [PubMed] [Google Scholar]
35. Pierce JP, Stefanick ML, Flatt SW, et al. Greater survival after breast cancer in physically active women with high vegetable-fruit intake regardless of obesity. J Clin Oncol. 2007;25(17):2345–2351. [PMC free article] [PubMed] [Google Scholar]
36. Pierce JP, Natarajan L, Caan BJ, et al. Influence of a diet very high in vegetables, fruit, and fiber and low in fat on prognosis following treatment for breast cancer: the Women's Healthy Eating and Living (WHEL) randomized trial. JAMA. 2007;298(3):289–298. [PMC free article] [PubMed] [Google Scholar]
37. Pierce JP. Diet and breast cancer prognosis: making sense of the Women's Healthy Eating and Living and Women's Intervention Nutrition Study trials. Curr Opin Obstet Gynecol. 2009;21(1):86–91. [PMC free article] [PubMed] [Google Scholar]
Source: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2874068/
0 Response to "Is It Ok for a Breast Cancer Patient to Eat Beef That Is Soybean Fed"
Postar um comentário